| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 5th February 2021 | R Neil Williams | 500 | Open or private sale | $400.60 | $200,300.00 |
| 5th February 2021 | R Neil Williams | 2,388 | Exercise of derivative | $12.30 | $29,372.40 |
| 5th February 2021 | R Neil Williams | 300 | Open or private sale | $405.95 | $121,785.00 |
| 5th February 2021 | R Neil Williams | 300 | Open or private sale | $401.62 | $120,486.00 |
| 5th February 2021 | R Neil Williams | 100 | Open or private sale | $398.16 | $39,816.00 |
| 5th February 2021 | R Neil Williams | 400 | Open or private sale | $404.36 | $161,744.00 |
| 5th February 2021 | R Neil Williams | 88 | Open or private sale | $406.90 | $35,807.20 |
| 5th February 2021 | R Neil Williams | 400 | Open or private sale | $399.63 | $159,852.00 |
| 5th February 2021 | R Neil Williams | 300 | Open or private sale | $396.50 | $118,950.00 |
| 4th February 2021 | R Neil Williams | 688 | Open or private sale | $396.84 | $273,025.92 |
Amyris
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.
Amyris, Inc. offers its products to health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003.
Ticker: AMRS
Sector: Basic Materials
Industry: Specialty Chemicals
SEC Central Index Key (CIK): 1365916
Employees: 503
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Revenue From Related Parties of $56 Th for the period Apr 2020 to Jun 2020 in the context of Product
Revenue From Related Parties of $0 for the period Apr 2020 to Jun 2020 in the context of Licenses and royalties
Revenue From Related Parties of $1 M for the period Apr 2020 to Jun 2020 in the context of Grants and collaborations
Revenue From Related Parties of $1 M for the period Apr 2020 to Jun 2020 in the context of all up
Revenue From Related Parties of $105 Th for the period Jan 2020 to Jun 2020 in the context of Product
Revenue From Related Parties of $4 M for the period Jan 2020 to Jun 2020 in the context of Licenses and royalties
Revenue From Related Parties of $4 M for the period Jan 2020 to Jun 2020 in the context of Grants and collaborations
Revenue From Related Parties of $8 M for the period Jan 2020 to Jun 2020 in the context of all up
Revenue From Related Parties of $0 for the period Apr 2019 to Jun 2019 in the context of Product
Revenue From Related Parties of $41 M for the period Apr 2019 to Jun 2019 in the context of Licenses and royalties
Revenue From Related Parties of $3 M for the period Apr 2019 to Jun 2019 in the context of Grants and collaborations
Revenue From Related Parties of $43 M for the period Apr 2019 to Jun 2019 in the context of all up
Revenue From Related Parties of $2 Th for the period Jan 2019 to Jun 2019 in the context of Product
Revenue From Related Parties of $40 M for the period Jan 2019 to Jun 2019 in the context of Licenses and royalties
Revenue From Related Parties of $3 M for the period Jan 2019 to Jun 2019 in the context of Grants and collaborations
Revenue From Related Parties of $43 M for the period Jan 2019 to Jun 2019 in the context of all up
Fundamentals
Cash at Carrying Value: $100 M (0%)
Inventory, Net: $33 M (0%)
Other Assets, Current: $3 M (29%)
Assets, Current: $191 M (159%)
Property, Plant and Equipment, Net: $27 M (0%)
Other Assets, Noncurrent: $6 M (0%)
Assets: $268 M (66%)
Long-term Debt, Current Maturities: $43 M (-4%)
Accounts Payable, Current: $23 M (-55%)
Accrued Liabilities, Current: $49 M (0%)
Liabilities, Current: $129 M (-19%)
Long-term Debt, Excluding Current Maturities: $24 M (-51%)
Other Liabilities, Noncurrent: $15 M (0%)
Liabilities: $327 M (-20%)
Common Stock, Value, Issued: $20 Th (66%)
Common Stock, Shares, Issued: $205 M (73%)
Retained Earnings (Accumulated Deficit): $2 B (-2%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $49 M (11%)
Stockholders' Equity (Parent): $67 M (-73%)
Liabilities and Equity: $268 M (66%)
Cost of Revenue: $23 M (-33%)
Research and Development: $17 M (-50%)
Operating Income/Loss: $41 M (-43%)
Other Income, net: $67 M (-45%)
Income before taxes: $108 M (-44%)
Provision for income taxes: $99 Th (-47%)
News
Amyris Changes The Cannabis Game And Hits New 52 Week High
10th February 2021
Amyris Is Setting Up For A Monster Run
17th December 2020